A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

NCT02584920 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non Hodgkin's Lymphoma

Interventions

DRUG: HLX01
DRUG: Rituximab

Sponsor

Shanghai Henlius Biotech